Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | Izuralimab |
Synonyms | |
Therapy Description |
Izuralimab (XmAb23104) is a bispecific antibody that binds to PD-1 (PDCD1) and ICOS (inducible T-cell costimulator, CD278), potentially resulting in enhanced anti-tumor immune response (Cancer Res 2018;78(13 Suppl):Abstract nr 2784). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
Izuralimab | XmAb 23104|XmAb23104 | PD-L1/PD-1 antibody 121 | Izuralimab (XmAb23104) is a bispecific antibody that binds to PD-1 (PDCD1) and ICOS (inducible T-cell costimulator, CD278), potentially resulting in enhanced anti-tumor immune response (Cancer Res 2018;78(13 Suppl):Abstract nr 2784). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT05879185 | Phase II | Izuralimab | A Study of XmAb23104 in People With Sarcoma | Terminated | USA | 0 |
NCT03752398 | Phase I | Izuralimab | A Study of XmAb23104 in Subjects With Selected Advanced Solid Tumors (DUET-3) (DUET-3) | Completed | USA | 0 |